source
- AstraZeneca ends phase 3 lung cancer trial after bispecific falls short versus KeytrudaAstraZeneca has stopped a phase 3 trial of volrustomig in lung cancer based on interim efficacy data, narrowing the opportunity for a bispecific designed to replace current immune checkpoint inhibi…Fierce Biotech · 7h ago↗ source
- BioCryst to rely on external partnerships after ending internal discovery programsBioCryst Pharmaceuticals CEO Charlie Gayer told Fierce that the company remains committed to science and research even as it shuts down its internal discovery efforts. Earlier this year the firm’s…
- Zealand Pharma sells its rights to Takeda's rusfertide for $100 million ahead of FDA decision